Science Corp. Secures $230 Million Series C Funding Round
Science Corp., a biotech startup developing brain-computer interface technologies, has raised $230 million in a Series C funding round, according to Crunchbase News. This round, led by investors including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital, increases the company’s total funding to $489 million since its founding in 2021. The funding highlights ongoing investor interest in deeptech innovations as the company advances its neural interface devices.
Funding Round Overview
The $230 million Series C round builds on a prior $104 million convertible note round led by Khosla Ventures. Science Corp., based in Alameda, California, has rapidly scaled since 2021, amassing resources for biotech development. Key investors such as Lightspeed Venture Partners and Y Combinator have reaffirmed their support, with Khosla Ventures participating in multiple rounds. This investor composition reflects trends in venture capital, where deeptech sectors are attracting backing. The round’s scale demonstrates the company’s progress and the appeal of its technologies.
Company Background and Innovations
Science Corp. focuses on advanced brain-implant systems and retinal implants to address severe medical conditions, including eye diseases. The company’s founders, Max Hodak—a co-founder of Neuralink—and Alan Mardinly, a former Neuralink executive, bring expertise in neurotechnology. Additionally, Science Corp. has acquired MEMS facility assets in North Carolina, enabling in-house manufacturing of chips for its neural interface devices. This acquisition enhances operational control and positions the company as a vertically integrated player in the biotech industry.
